22

Treatment of Hodgkin’s lymphoma (HL) has evolved in recent years, with modern treatments combining less toxic chemotherapy and radiation, leading to improved long-term disease-free survival. However, there is a higher chance of secondary cancer, especially breast cancer, following effective HL treatment. The impact of reduced radiation doses and volumes, as well as the use of advanced irradiation techniques, on the risk of secondary malignancy is not clear. According to medical organizations, previous chest irradiation is a contraindication to conservative breast treatment in women with initial breast cancer, essentially leaving mastectomy as the only viable treatment option. In this article, we present a discussion between radiation oncologists and surgeons on the major trials and recent developments regarding the prevalence of breast cancer following HL therapy, the risk of contralateral cancer, the feasibility of conservative treatment, and breast reconstruction modalities.